How Does CAR-T Cell Therapy for Chronic Lymphocytic Leukemia (CLL) Work? What the Evidence Shows

In March 2024, the FDA approved lisocabtagene maraleucel (Breyanzi) as the first CAR-T cell therapy for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) — a milestone for a disease that CAR-T had struggled to crack for nearly a decade. This article explains how the therapy is engineered, walks through what the pivotal TRANSCEND CLL 004 trial actually found in a heavily pretreated, high-risk patient population, and is equally clear about the approval's limits: it is accelerated (not full) approval, the response rates are real but modest compared to CAR-T's results in other blood cancers, and the safety profile — including cytokine release syndrome, neurologic toxicity, and a newer FDA-mandated warning about secondary T-cell malignancies — requires careful weighing against the alternative of continuing to cycle through targeted drugs.

Why CLL Resisted CAR-T for So Long

CAR-T cell therapy had already transformed treatment for acute lymphoblastic leukemia and large B-cell lymphoma by the mid-2010s, but chronic lymphocytic leukemia proved a harder target. CLL cells actively suppress the immune system, and, more specifically, they damage the very T cells that would need to be collected and re-engineered to fight the cancer — a phenomenon researchers describe as T-cell dysfunction or "exhaustion" that is often more severe in CLL patients than in other leukemias, in part because many have already been heavily treated with prior lines of chemotherapy or targeted agents by the time CAR-T is considered. Early single-arm studies of CD19-directed CAR-T in CLL through the 2010s showed responses were achievable but inconsistent, and no product reached approval. That changed with Bristol Myers Squibb's TRANSCEND CLL 004 trial, which tested lisocabtagene maraleucel (liso-cel) specifically in patients who had already failed both a Bruton's tyrosine kinase (BTK) inhibitor (such as ibrutinib) and a BCL-2 inhibitor (venetoclax) — a group with genuinely few remaining options and historically poor outcomes.

How Liso-Cel Is Made and Delivered

Like other approved CAR-T products, lisocabtagene maraleucel is manufactured individually for each patient. T cells are collected from the patient's blood via apheresis, then genetically engineered in a lab to express a chimeric antigen receptor targeting CD19, a protein found on the surface of CLL cells (as well as normal B cells). The engineered cells are expanded into a personalized dose, and the patient undergoes lymphodepleting chemotherapy (typically fludarabine and cyclophosphamide) in the days before infusion to make room for the CAR-T cells to expand and function. Liso-cel is distinctive among approved CAR-T products for its defined composition: it is manufactured as a formulated 1:1 ratio of CD8-positive and CD4-positive T-cell components, a design intended to produce a more consistent and predictable product from patient to patient rather than the variable mix that results from less controlled manufacturing.

What TRANSCEND CLL 004 Actually Showed

The trial enrolled adults with relapsed or refractory CLL or SLL, most of whom had already been through multiple prior therapies, including both a BTK inhibitor and venetoclax — precisely the double-refractory population the FDA ultimately approved the drug for. Among the 65 patients evaluable for the pivotal efficacy analysis, 20% achieved a complete response (95% CI, 11.1%–31.8%), and the overall response rate was 45% (95% CI, 32.3%–57.5%). Those numbers deserve context: this is a genuinely difficult-to-treat, previously heavily pretreated population, and a one-in-five chance of a complete response — a result that, when it happens, tends to be durable — is a meaningful outcome for patients who had exhausted the two major approved drug classes for CLL. Encouragingly, among patients who achieved a complete response, essentially all reached undetectable minimal residual disease (MRD): 100% MRD-negativity in peripheral blood and 92.3% in bone marrow, a depth of response that historically correlates with longer remission in CLL. Median duration of response reached 35.3 months in the trial's reporting, suggesting that patients who do respond well tend to stay in remission for a substantial period rather than relapsing quickly. Longer-term follow-up analyses presented at hematology conferences, using a broader efficacy population and later data cuts, have reported somewhat different response figures (response rates in the high-40% range and MRD-negativity closer to 60% across the full treated group) — a reminder that trial statistics shift somewhat as follow-up data matures, and that the specific numbers in liso-cel's FDA label reflect a defined analysis population and time point, not the final word on the drug's ceiling.

The Safety Picture: Real Risks That Come With Real Benefit

None of this comes without cost. In the 89 patients evaluated for safety, cytokine release syndrome (CRS) — a systemic inflammatory reaction driven by the rapid activation of CAR-T cells — occurred in 83% of patients at any grade, though severe (grade 3) CRS occurred in only 9%, with no grade 4 or 5 events reported. CRS typically began around a median of 4 days after infusion and resolved within a median of 6 days, patterns consistent with what's seen in CAR-T therapy for other blood cancers. Neurologic events, including confusion, tremor, and in some cases more severe encephalopathy (the syndrome now generally called ICANS), occurred in 46% of patients overall, with grade 3 severity in 20% and one grade 4 case; there were no fatal neurologic events reported in the trial. These events also emerged on a predictable early timeline (median onset around 7 days) and were generally manageable with supportive care and, when needed, steroids or tocilizumab. Cytopenias (low blood cell counts) and increased infection risk from both the lymphodepleting chemotherapy and the CAR-T cells' effects on normal B cells are also expected complications requiring monitoring for weeks to months after infusion. Separately, in 2024 the FDA required a new class-wide boxed warning across all approved CD19- and BCMA-directed CAR-T products, including Breyanzi, for the risk of secondary T-cell malignancies — a rare but serious concern identified through post-marketing safety surveillance across the CAR-T class as a whole, not unique to the CLL indication. This is a caution, not a reason for panic: the absolute risk appears low, and CAR-T's benefit-risk balance in heavily pretreated blood cancer patients remains favorable in the FDA's assessment, but it is a real safety signal patients and clinicians now factor into the decision.

What "Accelerated Approval" Means Here

It matters that the FDA approved liso-cel for CLL/SLL under its accelerated approval pathway, based on response rate and durability of response, rather than full approval based on a randomized trial demonstrating a survival benefit against standard therapy. Accelerated approval is a real and valuable regulatory tool — it gets promising therapies to patients with serious unmet need faster — but it comes with a formal expectation that confirmatory trials will verify the clinical benefit, and continued marketing approval is contingent on that verification. TRANSCEND CLL 004 was a single-arm, open-label, multicenter phase 1/2 study, meaning every patient who enrolled knew they were receiving liso-cel and there was no control group receiving an alternative treatment for direct comparison. That design is appropriate for an early-phase trial in a small, high-risk population, but it also means the current evidence cannot yet directly answer how liso-cel's overall survival compares to continuing other therapies in this same patient group — a question that later, more rigorous studies are intended to answer.

Bottom Line

Lisocabtagene maraleucel's approval for CLL/SLL is a genuine and hard-won advance: it gives patients who have already failed both a BTK inhibitor and venetoclax — a group that previously had very limited options — a new mechanism of attack, with a meaningful one-in-five chance of a complete, often MRD-negative and durable remission. That's real, and it deserves to be recognized as real. At the same time, this is an accelerated approval built on a single-arm trial in a small population, the CRS and neurologic toxicity rates are substantial (even though severe cases are a minority), and the drug now carries a class-wide FDA warning about secondary T-cell malignancy risk. For an appropriately selected, heavily pretreated patient working with a specialized CAR-T treatment center, the evidence supports considering liso-cel as a legitimate option. It does not yet support describing CAR-T as a cure for CLL or as safer or more effective than existing options in a head-to-head sense — those answers await the confirmatory data the FDA's accelerated pathway requires.